PolyPeptide Group AG - Asset Resilience Ratio

Latest as of June 2025: 9.92%

PolyPeptide Group AG (PPGN) has an Asset Resilience Ratio of 9.92% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read PPGN total liabilities for a breakdown of total debt and financial obligations.

Liquid Assets

CHF76.69 Million

≈ $96.96 Million USD Cash + Short-term Investments

Total Assets

CHF773.07 Million

≈ $977.37 Million USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2018–2024)

This chart shows how PolyPeptide Group AG's Asset Resilience Ratio has changed over time. See cash generation quality of PolyPeptide Group AG to measure how efficiently the company converts operating cash flow to free cash.

Liquid Assets Composition Over Time

This chart breaks down PolyPeptide Group AG's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see PPGN total assets.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	CHF76.69 Million	9.92%
Short-term Investments	CHF0.00	0%
Total Liquid Assets	CHF76.69 Million	9.92%

Asset Resilience Insights

Limited Liquidity: PolyPeptide Group AG maintains only 9.92% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company primarily holds liquidity in cash and equivalents rather than short-term investments.

PolyPeptide Group AG Industry Peers by Asset Resilience Ratio

Compare PolyPeptide Group AG's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Jiangsu Nhwa Pharmaceutical Co Ltd SHE:002262	Drug Manufacturers - Specialty & Generic	26.45%
Neuland Laboratories Limited NSE:NEULANDLAB	Drug Manufacturers - Specialty & Generic	9.65%
Shandong Buchang Pharmaceuticals Co Ltd SHG:603858	Drug Manufacturers - Specialty & Generic	3.47%
Hunan Warrant Pharmaceutical Co. Ltd. A SHG:688799	Drug Manufacturers - Specialty & Generic	0.40%
Bide Pharmatech Co. Ltd. A SHG:688073	Drug Manufacturers - Specialty & Generic	9.46%
Luye Pharma Group Ltd F:LUP	Drug Manufacturers - Specialty & Generic	9.15%
Jiangsu Jibeier Pharmaceutical Co Ltd SHG:688566	Drug Manufacturers - Specialty & Generic	2.98%
Shanxi Zhendong Pharmaceutical SHE:300158	Drug Manufacturers - Specialty & Generic	10.74%

Annual Asset Resilience Ratio for PolyPeptide Group AG (2018–2024)

The table below shows the annual Asset Resilience Ratio data for PolyPeptide Group AG.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2024-12-31	9.02%	CHF68.28 Million ≈ $86.32 Million	CHF756.58 Million ≈ $956.52 Million	-4.86pp
2023-12-31	13.89%	CHF95.71 Million ≈ $121.00 Million	CHF689.09 Million ≈ $871.19 Million	+7.37pp
2022-12-31	6.52%	CHF37.53 Million ≈ $47.45 Million	CHF575.78 Million ≈ $727.94 Million	-16.39pp
2021-12-31	22.91%	CHF136.30 Million ≈ $172.32 Million	CHF595.04 Million ≈ $752.29 Million	+18.33pp
2020-12-31	4.58%	CHF17.21 Million ≈ $21.76 Million	CHF375.98 Million ≈ $475.33 Million	-1.16pp
2019-12-31	5.74%	CHF17.51 Million ≈ $22.13 Million	CHF305.14 Million ≈ $385.78 Million	+2.20pp
2018-12-31	3.54%	CHF10.04 Million ≈ $12.69 Million	CHF283.83 Million ≈ $358.83 Million	--

pp = percentage points

About PolyPeptide Group AG

SW:PPGN Switzerland Drug Manufacturers - Specialty & Generic

Market Cap

$1.83 Billion

CHF1.45 Billion CHF

Market Cap Rank

#9871 Global

#126 in Switzerland

Share Price

CHF43.90

Change (1 day)

-0.34%

52-Week Range

CHF21.95 - CHF49.40

All Time High

CHF143.30